Reformulary Group announces Cannabis Standard, Canada’s first evidence-based medical cannabis formulary

X

RePort

Informed business decisions.

Subscription that provides data insights to help pharma make informed decisions.

Rapid access

React in near real-time with rapid, online access within days of month’s end.

Validated data, guaranteed

Get accurate, unprojected data that is cleaned and validated, using a full data set of 11 million Canadians.

Customized intelligence

Easily navigate between customized market dashboards and key performance indicators.

Turnkey technology

Log into RePort securely via the Web. There is nothing to install and no new systems to build.

Flexible subscription options

Rich database of prescription claims data for more than 10 million Canadians.

Healthcare analytics expertise

Leverage Reformulary’s extensive experience in healthcare, pharma, and actuarial science.